Active Biotech proposes a rights issue of convertible debentures totalling SEK 150 M


  • The Board proposes a rights issue of approximately 3.7 million convertible debentures with a total value of MSEK 150
  • The debentures shall be issued at a nominal value of SEK 40 and subscribed at the same price. One convertible debenture can be converted into one new share.
  • The entire issue is to be guaranteed by MGA Holding AB
Lund 15 September 2004
Active Biotech AB (publ)
For further information, please contact:
Sven Andréasson, President and CEO, telephone: +46 46-19 20 49
Hans Kolam, CFO, telephone: +46 46-19 20 44
Cecilia Hofvander, Manager Corporate Communication, telephone: +46 46-19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/ inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
The completepress release can be downloaded from the following link:

pdfPress Release (PDF)